CytomX Therapeutics (NASDAQ: CTMX) reported Q2 2026 revenue of $1.4 million, down from $18.7 million a year earlier, while diluted loss per share widened to $0.09 from a reported $0.00. Net loss increased to $20.7 million as collaboration revenue declined and R&D spending rose, while quarter-end cash, cash equivalents, and investments remained at $330.3 million before a $37.0 million Regeneron payment received in July.

Core financial results

For the three months ended June 30, 2026, the main financial change was a sharp decline in collaboration revenue. CytomX attributed this to the completion of its performance obligations under Bristol Myers Squibb collaborations during 2025 and lower research activity under the Astellas collaboration, which concluded in Q2 2026.

At the same time, operating expenses increased by $5.3 million. Most of that increase came from Varseta-M manufacturing, higher personnel costs, and other research and development activities; consulting and rent also raised general and administrative expenses.

Interest income increased to $3.2 million from $1.2 million and partly offset the operating loss, but it was not enough to counter the combination of lower revenue and higher development spending.

Pipeline and collaboration progress

Varseta-M development expands beyond late-line colorectal cancer

Enrollment in the Varseta-M Phase 1 monotherapy study was completed with 113 patients across dose-escalation, expansion, and optimization cohorts. The dose-optimization cohorts enrolled 40 patients across the 8.6 mg/kg and 10 mg/kg every-three-week doses as of the end of April 2026.

CytomX expects to provide a Phase 1 update by the end of 2026, with the results intended to support dose selection for later-stage development. The company plans to engage with the FDA regarding its first monotherapy registrational study in colorectal cancer, which it aims to begin in the first half of 2027.

The company is also broadening the program through:

• An ongoing Phase 1 study combining Varseta-M with bevacizumab in third-line or later metastatic colorectal cancer, with initial data anticipated in the first half of 2027.
• A Phase 1/2 study of Varseta-M with bevacizumab, 5-fluorouracil, and leucovorin in second-line metastatic colorectal cancer, scheduled to begin in Q4 2026.
• Phase 1 monotherapy expansion cohorts in gastric and gastroesophageal junction cancers, EpCAM-selected pancreatic ductal adenocarcinoma, and EpCAM-selected biliary tract cancer, beginning in Q3 2026.

CX-801 advances through early dose escalation

The CX-801 Phase 1 monotherapy study in advanced melanoma reached its fourth dose level. CytomX reported that the treatment had generally been well tolerated at dose levels exceeding the approved dose of unmasked interferon alpha-2b.

The CX-801 combination study with Keytruda cleared its third dose level and continues to enroll patients. Initial combination data are expected in the first half of 2027.

Regeneron collaboration adds targets and near-term funding

CytomX expanded its Regeneron collaboration in June 2026 to cover additional masked bispecific immunotherapy programs. The company received a $37.0 million target-selection payment in July for two additional programs, after the Q2 balance-sheet date.

Regeneron also obtained an option to select as many as six additional targets. The collaboration now covers up to approximately $4.0 billion in potential target-nomination, research, development, regulatory, and sales-based milestones, although those payments remain contingent on future progress.

Profitability, liquidity, and balance sheet

Cash, cash equivalents, and investments totaled $330.3 million at June 30, down $16.4 million from $346.7 million at March 31. The Q2 balance consisted of $17.2 million in cash and equivalents and $313.1 million in short-term investments.

The balance excludes the $37.0 million Regeneron payment received in July. CytomX expects its existing resources to provide a cash runway to at least the second half of 2028, giving the company time to reach several planned Varseta-M and CX-801 clinical milestones.

The runway nevertheless depends on future development costs. Q2 already showed higher spending on Varseta-M manufacturing and personnel, and advancing multiple expansion and combination studies could keep R&D expenses elevated.

Recent insider transactions

The supplied insider dataset reports no purchases during the past six months. Its aggregate summary also shows zero sales, but that conflicts with the detailed transaction records listing five sales between March and June 2026; the table below therefore presents the detailed entries without drawing conclusions about management’s outlook.

Risks investors should monitor

• Early-stage clinical risk: Varseta-M and CX-801 remain in Phase 1 development. Initial safety or efficacy findings may not be replicated in larger or later-stage studies.
• Dose selection and regulatory execution: CytomX still needs to select a Varseta-M dose and align with the FDA on the design and regulatory pathway for its planned registrational colorectal cancer study.
• Collaboration-related revenue volatility: Q2 revenue fell after the completion of Bristol Myers Squibb obligations and reduced Astellas activity. Future collaboration revenue may continue to depend on the timing of research work and contingent payments.
• Higher development costs: Varseta-M manufacturing and personnel expenses increased during the quarter. Running additional combination and indication-expansion studies could place further pressure on operating losses and the projected cash runway.
• Pipeline concentration: CytomX’s clinical progress depends heavily on Varseta-M and CX-801, making upcoming data and trial execution central to the company’s operating outlook.

Summary

CytomX’s Q2 2026 results were defined by lower collaboration revenue and higher pipeline investment, which substantially widened operating and net losses. Its $330.3 million quarter-end liquidity, supplemented by the subsequent Regeneron payment, supports the stated runway into at least the second half of 2028. The next major points to monitor are the year-end Varseta-M update and dose selection, the start of new colorectal and gastrointestinal cancer cohorts, and whether development spending remains consistent with that runway.

Find out more